OBIO
Orchestra BioMed Holdings, Inc.
Price Chart
Latest Quote
$4.07
-0.01 (-0.25%)
Current Price
| Previous Close | $4.08 |
| Open | $4.02 |
| Day High | $4.12 |
| Day Low | $3.94 |
| Volume | 18,963 |
Stock Information
| Shares Outstanding | 59.88M |
| Total Debt | $15.85M |
| Cash Equivalents | $94.40M |
| Revenue | $32.72M |
| Net Income | $-54.89M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $243.71M |
| EPS (TTM) | $-0.95 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $175.53M |
| Sales | $32.72M |
| Income | $-54.89M |
| Book/sh | $0.70 |
| Cash/sh | $1.58 |
| Employees | 86 |
Financial Ratios
| Quick Ratio | 6.90 |
| Current Ratio | 7.03 |
| Debt/Eq | 31.10 |
Returns & Margins
| ROA | -43.02% |
| ROE | -161.12% |
| Gross Margin | 99.46% |
| Operating Margin | -20069.09% |
| Profit Margin | -166.96% |
Ownership
| Insider Ownership | 26.13% |
| Institutional Ownership | 41.69% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.79 |
| P/S | 7.45 |
| P/B | 5.79 |
Analyst Data
| Recommendation | none |
| Target Price | $12.17 |
Technical Indicators
| SMA20 | $3.97 |
| SMA50 | $4.05 |
| SMA200 | $3.98 |
| RSI | 58.16 |
| ATR | 0.1882 |
| Shares Float | 32.78M |
| Short Float | 2.58% |
| Short Ratio | 3.64 |
| Volatility | 0.50 |
| Rel Volume | 0.08 |
Performance History
| Week | +2.52% |
| Month | -0.73% |
| Quarter | -14.50% |
| 6 Months | -6.22% |
| YTD | -5.57% |
| Year | +35.22% |
| 3 Years | -62.69% |
| 5 Years | -60.33% |
| 10 Years | -64.30% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $4.07 | 18,963 |
| 2026-06-22 | $4.08 | 260,400 |
| 2026-06-18 | $3.99 | 319,600 |
| 2026-06-17 | $3.87 | 270,800 |
| 2026-06-16 | $3.85 | 479,400 |
| 2026-06-15 | $3.97 | 157,000 |
| 2026-06-12 | $4.10 | 556,200 |
| 2026-06-11 | $4.07 | 163,500 |
| 2026-06-10 | $4.02 | 288,700 |
| 2026-06-09 | $4.03 | 187,800 |
| 2026-06-08 | $3.95 | 104,500 |
| 2026-06-05 | $3.90 | 138,800 |
| 2026-06-04 | $3.99 | 152,700 |
| 2026-06-03 | $3.86 | 240,600 |
| 2026-06-02 | $3.91 | 183,900 |
| 2026-06-01 | $3.83 | 292,700 |
| 2026-05-29 | $3.91 | 193,000 |
| 2026-05-28 | $3.98 | 124,100 |
| 2026-05-27 | $3.95 | 135,300 |
| 2026-05-26 | $3.97 | 351,500 |
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
đ° Latest News
Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock
Simply Wall St. âĸ 2026-05-21T11:10:59Z
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-12T21:40:05Z
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-07T23:05:10Z
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-06T12:25:09Z
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-04-30T12:30:10Z
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates
Zacks âĸ 2026-03-12T13:35:01Z
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
Zacks âĸ 2026-03-11T21:35:02Z
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest shareholders are retail investors with 41% ownership, institutions own 17%
Simply Wall St. âĸ 2026-01-22T11:17:39Z
TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs
Insider Monkey âĸ 2025-12-31T16:13:02Z
Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements
Insider Monkey âĸ 2025-11-29T06:25:58Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $190,000 | $204,000 | $186,000 | $211,000 |
| Cost Of Revenue | $190,000 | $204,000 | $186,000 | $211,000 |
| Total Revenue | $33,482,000 | $2,638,000 | $2,760,000 | $3,533,000 |
| Operating Revenue | $33,482,000 | $2,638,000 | $2,760,000 | $3,533,000 |
| Expenses | ||||
| Interest Expense | $1,148,000 | - | - | - |
| Total Expenses | $85,289,000 | $66,939,000 | $54,266,000 | $36,190,000 |
| Other Income Expense | $254,000 | $-79,000 | $-1,463,000 | $-1,001,000 |
| Net Non Operating Interest Income Expense | $-1,148,000 | $3,356,000 | $3,849,000 | $50,000 |
| Interest Expense Non Operating | $1,148,000 | - | - | - |
| Operating Expense | $85,099,000 | $66,735,000 | $54,080,000 | $35,979,000 |
| Other Non Operating Income Expenses | - | $-11,000 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-52,701,000 | $-61,024,000 | $-49,120,000 | $-33,608,000 |
| Net Interest Income | $-1,148,000 | $3,356,000 | $3,849,000 | $50,000 |
| Normalized Income | $-52,955,000 | $-60,956,000 | $-47,657,000 | $-32,607,000 |
| Net Income From Continuing And Discontinued Operation | $-52,701,000 | $-61,024,000 | $-49,120,000 | $-33,608,000 |
| Total Operating Income As Reported | $-51,807,000 | $-64,301,000 | $-51,506,000 | $-32,657,000 |
| Net Income Common Stockholders | $-52,955,000 | $-61,024,000 | $-49,120,000 | $-33,608,000 |
| Net Income | $-52,701,000 | $-61,024,000 | $-49,120,000 | $-33,608,000 |
| Net Income Including Noncontrolling Interests | $-52,701,000 | $-61,024,000 | $-49,120,000 | $-33,608,000 |
| Net Income Continuous Operations | $-52,701,000 | $-61,024,000 | $-49,120,000 | $-33,608,000 |
| Pretax Income | $-52,701,000 | $-61,024,000 | $-49,120,000 | $-33,608,000 |
| Operating Income | $-51,807,000 | $-64,301,000 | $-51,506,000 | $-32,657,000 |
| Gross Profit | $33,292,000 | $2,434,000 | $2,574,000 | $3,322,000 |
| Interest Income | - | $3,356,000 | $3,849,000 | $50,000 |
| Special Income Charges | - | $0 | $-1,151,000 | $-682,000 |
| Interest Income Non Operating | - | $3,356,000 | $3,849,000 | $50,000 |
| Per Share | ||||
| Diluted EPS | $-1.11 | $-1.66 | $-1.48 | $-1.06 |
| Basic EPS | $-1.11 | $-1.66 | $-1.48 | $-1.06 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-51,480,000 | $-63,925,000 | $-49,756,000 | $-31,434,000 |
| Total Unusual Items | $254,000 | $-68,000 | $-1,463,000 | $-1,001,000 |
| Total Unusual Items Excluding Goodwill | $254,000 | $-68,000 | $-1,463,000 | $-1,001,000 |
| Reconciled Depreciation | $327,000 | $308,000 | $287,000 | $222,000 |
| EBITDA (Bullshit earnings) | $-51,226,000 | $-63,993,000 | $-51,219,000 | $-32,435,000 |
| EBIT | $-51,553,000 | $-64,301,000 | $-51,506,000 | $-32,657,000 |
| Diluted Average Shares | $47,747,078 | $36,821,042 | $33,225,227 | $31,614,079 |
| Basic Average Shares | $47,747,078 | $36,821,042 | $33,225,227 | $31,614,079 |
| Diluted NI Availto Com Stockholders | $-52,955,000 | $-61,024,000 | $-49,120,000 | $-33,608,000 |
| Preferred Stock Dividends | $254,000 | - | - | - |
| Gain On Sale Of Security | $254,000 | $-68,000 | $-312,000 | $-319,000 |
| Research And Development | $58,185,000 | $42,804,000 | $33,822,000 | $21,945,000 |
| Selling General And Administration | $26,914,000 | $23,931,000 | $20,258,000 | $14,034,000 |
| Other Special Charges | - | - | $1,151,000 | $682,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $53,570,000 | $32,958,000 | $68,043,000 | $52,534,000 |
| Total Assets | $114,857,000 | $76,173,000 | $95,212,000 | $95,572,000 |
| Total Non Current Assets | $6,946,000 | $7,002,000 | $6,098,000 | $10,882,000 |
| Other Non Current Assets | $1,240,000 | $1,020,000 | $769,000 | $4,711,000 |
| Investmentin Financial Assets | $2,495,000 | $2,495,000 | $2,495,000 | $2,495,000 |
| Current Assets | $107,911,000 | $69,171,000 | $89,114,000 | $84,690,000 |
| Other Current Assets | $994,000 | $2,094,000 | $1,274,000 | $533,000 |
| Inventory | $310,000 | $173,000 | $146,000 | $276,000 |
| Receivables | $95,000 | $92,000 | $99,000 | $96,000 |
| Accounts Receivable | $95,000 | $92,000 | $99,000 | $96,000 |
| Cash Cash Equivalents And Short Term Investments | $106,512,000 | $66,812,000 | $87,595,000 | $83,785,000 |
| Cash And Cash Equivalents | $34,690,000 | $22,261,000 | $30,559,000 | $19,784,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $15,955,000 | $16,529,000 | $1,687,000 | $11,870,000 |
| Long Term Debt And Capital Lease Obligation | $15,204,000 | $15,979,000 | $1,038,000 | $11,173,000 |
| Long Term Debt | $14,268,000 | $14,292,000 | - | $9,490,000 |
| Current Debt And Capital Lease Obligation | $751,000 | $550,000 | $649,000 | $697,000 |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $61,287,000 | $43,215,000 | $27,169,000 | $43,038,000 |
| Total Non Current Liabilities Net Minority Interest | $44,551,000 | $27,008,000 | $15,961,000 | $24,472,000 |
| Other Non Current Liabilities | $16,790,000 | $40,000 | - | $196,000 |
| Derivative Product Liabilities | $2,749,000 | $0 | - | - |
| Non Current Deferred Liabilities | $0 | $10,989,000 | $14,923,000 | $13,103,000 |
| Current Liabilities | $16,736,000 | $16,207,000 | $11,208,000 | $18,566,000 |
| Current Deferred Liabilities | $0 | $4,439,000 | $2,510,000 | $6,436,000 |
| Payables And Accrued Expenses | $11,825,000 | $8,606,000 | $5,388,000 | $6,864,000 |
| Payables | $6,095,000 | $5,134,000 | $2,900,000 | $3,968,000 |
| Accounts Payable | $6,095,000 | $5,134,000 | $2,900,000 | $3,968,000 |
| Other Current Liabilities | - | - | - | $2,089,000 |
| Total Tax Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $53,570,000 | $32,958,000 | $68,043,000 | $52,534,000 |
| Total Equity Gross Minority Interest | $53,570,000 | $32,958,000 | $68,043,000 | $52,534,000 |
| Stockholders Equity | $53,570,000 | $32,958,000 | $68,043,000 | $52,534,000 |
| Gains Losses Not Affecting Retained Earnings | $60,000 | $52,000 | $-10,000 | $-8,000 |
| Other Equity Adjustments | $60,000 | $52,000 | $-10,000 | $-8,000 |
| Retained Earnings | $-362,579,000 | $-309,878,000 | $-248,854,000 | $-199,734,000 |
| Preferred Securities Outside Stock Equity | $9,808,000 | $0 | - | - |
| Other | ||||
| Ordinary Shares Number | $57,032,963 | $38,194,442 | $35,777,412 | $31,614,079 |
| Share Issued | $57,032,963 | $38,194,442 | $35,777,412 | $31,614,079 |
| Tangible Book Value | $53,570,000 | $32,958,000 | $68,043,000 | $52,534,000 |
| Invested Capital | $67,838,000 | $47,250,000 | $68,043,000 | $62,024,000 |
| Working Capital | $91,175,000 | $52,964,000 | $77,906,000 | $66,124,000 |
| Capital Lease Obligations | $1,687,000 | $2,237,000 | $1,687,000 | $2,380,000 |
| Total Capitalization | $67,838,000 | $47,250,000 | $68,043,000 | $62,024,000 |
| Additional Paid In Capital | $416,083,000 | $342,780,000 | $316,903,000 | $252,274,000 |
| Capital Stock | $6,000 | $4,000 | $4,000 | $2,000 |
| Common Stock | $6,000 | $4,000 | $4,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $10,989,000 | $14,923,000 | $13,103,000 |
| Long Term Capital Lease Obligation | $936,000 | $1,687,000 | $1,038,000 | $1,683,000 |
| Current Deferred Revenue | $0 | $4,439,000 | $2,510,000 | $6,436,000 |
| Current Capital Lease Obligation | $751,000 | $550,000 | $649,000 | $697,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,160,000 | $2,612,000 | $2,661,000 | $2,480,000 |
| Current Accrued Expenses | $5,730,000 | $3,472,000 | $2,488,000 | $2,896,000 |
| Investments And Advances | $2,495,000 | $2,495,000 | $2,495,000 | $2,495,000 |
| Trading Securities | $2,495,000 | $2,495,000 | $2,495,000 | $2,495,000 |
| Net PPE | $3,211,000 | $3,487,000 | $2,834,000 | $3,676,000 |
| Accumulated Depreciation | $-1,631,000 | $-1,303,000 | $-1,044,000 | $-778,000 |
| Gross PPE | $4,842,000 | $4,790,000 | $3,878,000 | $4,454,000 |
| Leases | $159,000 | $159,000 | $203,000 | $191,000 |
| Other Properties | $4,239,000 | $4,187,000 | $3,332,000 | $3,899,000 |
| Machinery Furniture Equipment | $444,000 | $444,000 | $343,000 | $364,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $71,822,000 | $44,551,000 | $57,036,000 | $64,001,000 |
| Construction In Progress | - | - | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-49,452,000 | $-50,847,000 | $-46,205,000 | $-29,880,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-48,963,000 | $-50,558,000 | $-46,127,000 | $-29,289,000 |
| Cash Flow From Continuing Operating Activities | $-48,963,000 | $-50,558,000 | $-46,127,000 | $-29,289,000 |
| Operating Gains Losses | $-254,000 | - | $1,445,000 | $2,032,000 |
| Investing Activities | ||||
| Capital Expenditure | $-489,000 | $-289,000 | $-78,000 | $-591,000 |
| Investing Cash Flow | $-26,941,000 | $13,089,000 | $10,687,000 | $-64,122,000 |
| Cash Flow From Continuing Investing Activities | $-26,941,000 | $13,089,000 | $10,687,000 | $-64,122,000 |
| Net Other Investing Changes | - | $-602,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $71,880,000 | $15,035,000 | $0 | $109,830,000 |
| Financing Cash Flow | $88,333,000 | $29,171,000 | $46,215,000 | $103,257,000 |
| Cash Flow From Continuing Financing Activities | $88,333,000 | $29,171,000 | $46,215,000 | $103,257,000 |
| Net Other Financing Charges | $16,362,000 | $-1,104,000 | $56,810,000 | $-10,317,000 |
| Net Preferred Stock Issuance | $12,557,000 | $0 | - | - |
| Preferred Stock Issuance | $12,557,000 | $0 | - | - |
| Net Common Stock Issuance | $59,323,000 | $15,035,000 | $0 | $109,830,000 |
| Common Stock Issuance | $59,323,000 | $15,035,000 | $0 | $109,830,000 |
| Other | ||||
| Issuance Of Debt | $0 | $15,000,000 | $0 | $10,000,000 |
| Interest Paid Supplemental Data | $1,447,000 | $102,000 | $1,119,000 | $1,371,000 |
| End Cash Position | $34,690,000 | $22,261,000 | $30,559,000 | $19,784,000 |
| Beginning Cash Position | $22,261,000 | $30,559,000 | $19,784,000 | $9,938,000 |
| Changes In Cash | $12,429,000 | $-8,298,000 | $10,775,000 | $9,846,000 |
| Proceeds From Stock Option Exercised | $91,000 | $240,000 | $254,000 | $190,000 |
| Net Issuance Payments Of Debt | $0 | $15,000,000 | $-10,849,000 | $3,554,000 |
| Net Long Term Debt Issuance | $0 | $15,000,000 | $-10,849,000 | $3,554,000 |
| Long Term Debt Issuance | $0 | $15,000,000 | $0 | $10,000,000 |
| Net Investment Purchase And Sale | $-26,452,000 | $13,980,000 | $10,765,000 | $-63,531,000 |
| Sale Of Investment | $49,860,000 | $86,628,000 | $152,797,000 | $0 |
| Purchase Of Investment | $-76,312,000 | $-72,648,000 | $-142,032,000 | $-63,531,000 |
| Net PPE Purchase And Sale | $-489,000 | $-289,000 | $-78,000 | $-591,000 |
| Purchase Of PPE | $-489,000 | $-289,000 | $-78,000 | $-591,000 |
| Change In Working Capital | $-10,372,000 | $-765,000 | $-3,307,000 | $-451,000 |
| Change In Other Working Capital | $-15,428,000 | $-2,005,000 | $-2,106,000 | $-2,862,000 |
| Change In Other Current Liabilities | $-550,000 | $-652,000 | $-693,000 | $-319,000 |
| Change In Payables And Accrued Expense | $4,866,000 | $2,969,000 | $145,000 | $3,352,000 |
| Change In Prepaid Assets | $880,000 | $-1,071,000 | $-781,000 | $-439,000 |
| Change In Inventory | $-137,000 | $-28,000 | $131,000 | $-208,000 |
| Change In Receivables | $-3,000 | $22,000 | $-3,000 | $25,000 |
| Changes In Account Receivables | $-3,000 | $22,000 | $-3,000 | $25,000 |
| Other Non Cash Items | $2,059,000 | $240,000 | $-3,075,000 | $134,000 |
| Stock Based Compensation | $11,978,000 | $10,615,000 | $7,625,000 | $3,413,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $68,000 | $18,000 | $-1,031,000 |
| Depreciation Amortization Depletion | $327,000 | $308,000 | $287,000 | $222,000 |
| Depreciation And Amortization | $327,000 | $308,000 | $287,000 | $222,000 |
| Gain Loss On Investment Securities | $-254,000 | - | $294,000 | $1,350,000 |
| Net Income From Continuing Operations | $-52,701,000 | $-61,024,000 | $-49,120,000 | $-33,608,000 |
| Repayment Of Debt | - | $0 | $-10,849,000 | $-6,446,000 |
| Long Term Debt Payments | - | $0 | $-10,849,000 | $-6,446,000 |
| Change In Payable | - | - | - | - |
| Change In Account Payable | - | - | - | - |
Fetched: 2026-06-23